Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Lexogen and Partek Deliver QuantSeq Analysis Solution

Partek Incorporated
Posted on: 28 Nov 17

Partek and Lexogen scientists have joined forces to deliver an easy-to-use analysis pipeline in Partek® Flow® software for data generated by Lexogen’s QuantSeq 3’ Library Prep Kits. QuantSeq is an economical protocol for RNA-Seq gene expression analysis and provides an alternative to microarrays. This pipeline enables Lexogen customers to import raw sequencing files directly into Partek Flow to automate analysis and removes the barrier for those without an advanced bioinformatics background.

Scientists at Lexogen and Partek collaborated closely to create the pipeline. The pipeline includes removal of poly-A tails and sequencing adaptors, trimming reads based on quality, aligning reads to any reference genome using the STAR aligner, and mapping reads to any public or custom transcriptome database. Users can then use the comprehensive statistics and interactive visualizations within Partek Flow to explore and interpret the biological implications of the data.

“Partek Flow is an NGS data analysis software known to researchers in this area. We are pleased to announce that a QuantSeq data analysis pipeline for differential gene expression analysis is now available to all Partek Flow users,” said Dalia Daujotyte, Head of Business Development at Lexogen.

When asked about the pipeline, DJ Meyer, Vice President of Sales at Partek said, “We are excited to offer a start-to-finish analysis pipeline for Lexogen QuantSeq customers in Partek Flow. With the strength of Lexogen’s expression profiling and the ease-of-use of Partek Flow, scientists can now perform rigorous bioinformatics analysis of QuantSeq data without the assistance of an informatics team.” Meyer also said, “Partek is looking forward to further successful collaborations with Lexogen scientists.”

There will be a webinar on December 14th where scientists from Partek and Lexogen will demonstrate the pipeline and conduct a live question and answer session. Details can be found here.

To use the Lexogen QuantSeq analysis pipeline, users must first have an active license or trial of Partek Flow software.

About Partek Incorporated

Partek Incorporated (www.partek.com) develops and globally markets quality analysis software and services for life sciences research. Partek software is unique in supporting all major microarray and next-generation sequencing platforms. Over six thousand peer-reviewed scientific papers have used our software to streamline the analysis of Gene Expression, miRNA Expression, Copy Number, Allele-Specific Copy Number, LOH, Association, Trio analysis, ChIP-Seq, RNA-Seq, scRNA-Seq, DNA-Seq, DNA Methylation, and qPCR studies. Partek, headquartered in St. Louis, MO, USA, has been turning data into discovery® since 1993.

About Lexogen

Lexogen is a transcriptomics and next-generation sequencing company, focusing on the development of technologies for complete transcriptome sequencing. Their portfolio includes innovative molecular biology kits, software, and services for RNA-Seq.

To learn more, visit www.lexogen.com and follow @lexogen.

Partek, Partek Flow, and “turning data into discovery” are trademarks of Partek Incorporated. The names of other companies or products mentioned herein may be the trademarks of their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005153/en/

Business Wire
www.businesswire.com

Last updated on: 28/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.